Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
Q : How is Taysha Gene Therapies considering endpoints for their trials given the heterogeneity of Rett syndrome? A : Sean Nolan, CEO, explained that they are considering the heterogeneity by potentially using patients as their own controls, supported by natural history data. They are focusing on milestones and functional gains, which can vary among patients but are consistent in showing improvement across the board. Q : Can you provide more context on the natural history analysis and its use as a comparator in trials? A : Sean Nolan stated that while the natural history data does not indicate a uniform progression like in SMA, it does show consistent patterns in loss or lack of gain of certain functions. This data will be used to inform trial design and endpoints, with further discussions planned with the FDA. Q : What is the safety profile of the high dose of TSHA 102, and is there a window for adverse events? A : Sukumar Nagendran, President & Head of R&D, noted that the high
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
TSHA
Earnings
- 11/13/24 - Miss
TSHA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- TSHA's page on the SEC website